PTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $93.00 at Bank of America

PTC Therapeutics (NASDAQ:PTCT) had its target price decreased by Bank of America from $97.00 to $93.00 in a research note released on Friday morning,Benzinga reports. Bank of America currently has a buy rating on the biopharmaceutical company’s stock.

PTCT has been the subject of a number of other reports. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Barclays upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $68.00 to $119.00 in a research report on Tuesday, January 27th. Morgan Stanley reissued an “overweight” rating and set a $90.00 price target on shares of PTC Therapeutics in a research note on Thursday, January 8th. Royal Bank Of Canada downgraded PTC Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their price objective for the stock from $82.00 to $91.00 in a report on Monday, December 1st. Finally, The Goldman Sachs Group increased their target price on PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a report on Wednesday, November 5th. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $80.73.

PTC Therapeutics Price Performance

PTCT stock opened at $70.66 on Friday. The firm has a 50 day simple moving average of $74.91 and a two-hundred day simple moving average of $67.91. The stock has a market cap of $5.67 billion, a PE ratio of 9.13 and a beta of 0.48. PTC Therapeutics has a one year low of $35.95 and a one year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 373.67%. The company had revenue of $164.68 million for the quarter, compared to analysts’ expectations of $281.45 million. During the same quarter last year, the business posted ($0.85) EPS. The business’s quarterly revenue was down 22.7% compared to the same quarter last year. On average, research analysts expect that PTC Therapeutics will post -4.52 EPS for the current fiscal year.

Insider Transactions at PTC Therapeutics

In related news, VP Mark Elliott Boulding sold 3,081 shares of PTC Therapeutics stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $213,698.16. Following the sale, the vice president owned 108,231 shares in the company, valued at $7,506,902.16. The trade was a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Pauwels sold 3,019 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $209,397.84. Following the transaction, the insider directly owned 77,122 shares in the company, valued at approximately $5,349,181.92. The trade was a 3.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 298,246 shares of company stock worth $23,393,870. Corporate insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On PTC Therapeutics

A number of large investors have recently modified their holdings of the stock. Empowered Funds LLC bought a new position in PTC Therapeutics in the first quarter worth about $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in PTC Therapeutics by 11.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock worth $9,109,000 after purchasing an additional 18,504 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in PTC Therapeutics by 22.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 12,545 shares of the biopharmaceutical company’s stock worth $613,000 after purchasing an additional 2,258 shares in the last quarter. AlphaQuest LLC raised its holdings in PTC Therapeutics by 337.7% in the second quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 6,102 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D lifted its position in PTC Therapeutics by 7.0% during the second quarter. State of New Jersey Common Pension Fund D now owns 41,376 shares of the biopharmaceutical company’s stock valued at $2,021,000 after buying an additional 2,701 shares during the period.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.